Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 12/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157356 | 0.95 | SOAT1 (0.91) | SOAT1POLBLMNATHRBSHMT2 | |
| SCHEMBL6278992 | 0.94 | SOAT1 (0.88) | SOAT1POLBLMNATHRBSHMT2 | |
| SCHEMBL6282168 | 0.90 | SOAT1 (0.81) | SOAT1POLBLMNATHRBSHMT2 | |
| SCHEMBL6280710 | 0.89 | SOAT1 (0.80) | SOAT1POLBLMNATHRBSHMT2 | |
| Hydrochloric Acid SCHEMBL6280620 | 0.88 | SOAT1 (0.79) | SOAT1POLBLMNATHRBSHMT2 | |
| SCHEMBL4513200 | 0.88 | SOAT1 (1.00) | SOAT1POLB | |
| Hydrochloric Acid SCHEMBL6282102 | 0.88 | SOAT1 (0.78) | SOAT1POLBLMNATHRBSHMT2 | |
| SCHEMBL6286182 | 0.83 | SOAT1 (0.91) | SOAT1POLB | |
| SCHEMBL6282774 | 0.83 | SOAT1 (0.78) | SOAT1POLBLMNA | |
| SCHEMBL4984886 | 0.83 | SOAT1 (0.70) | SOAT1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| EP-3823631-B1 | METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | ASTRAZENECA AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20240082278-A1 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | ASTRAZENECA AB (SE) | 2024-03-14 | — | — | US | disclosed |
| US-11826376-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | ASTRAZENECA AB (SE) | 2023-11-28 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1493448-A1 | MEDICINAL COMPOSITION COMPRISING ACAT INHIBITOR AND INSULINE RESISTANCE IMPROVING AGENT | Sankyo Company, Limited (JP) | 2005-01-05 | — | — | EP | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1431294-A1 | VASCULAR WALL-SELECTIVE ACAT INHIBITOR | Kowa Company Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| EP-1421953-A1 | MEDICINAL COMPOSITIONS CONTAINING ANGIOTENSIN II RECEPTOR ANTAGONIST | Sankyo Company, Limited (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826376-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | SLC5A2, SLC5A1, FABP3 | SOAT1 788/4885POLB 4497/4885LMNA 1459/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | SOAT1 384/4885POLB 4656/4885LMNA 3821/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT1 463/4885POLB 4467/4885LMNA 2937/4885 |
| US-20040198788-A1 | Medicinal compositions containing angiotensin II receptor antagonist | AGTR2, AGTR1, AGT | SOAT1 419/4885POLB 2721/4885LMNA 2856/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | SOAT1 462/4885POLB 4445/4885LMNA 2897/4885 |
| US-20240082278-A1 | METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | SLC5A2, SLC5A1, DPP4 | SOAT1 1012/4885POLB 4577/4885LMNA 1963/4885 |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | SLC5A2, SLC5A1, FABP3 | SOAT1 788/4885POLB 4497/4885LMNA 1459/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | SOAT1 384/4885POLB 4656/4885LMNA 3821/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT1 463/4885POLB 4467/4885LMNA 2937/4885 |
| US-20050119314-A1 | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | ACAT2, ACAT1, ACACA | SOAT1 48/4885POLB 2470/4885LMNA 1587/4885 |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | SOAT1 5/4885POLB 1313/4885LMNA 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.